18 completed, 8 unknown, 7 recruiting, 4 active not recruiting. 12 Phase 2, 7 Not applicable, 5 Phase 3, 4 Phase 4, 2 Phase 1.
Follow ACTH Syndrome, Ectopic: new trials by email Literature Review of ACTH Syndrome, Ectopic trials Research Report on ACTH Syndrome, Ectopic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS Metyrapone 250 mg Oral Tablets, Placebo - Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS) | Phase 2 | Recruiting | Mayo Clinic | 90 | 2026-10-01 | 2026-09-25 |
| Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome Osilodrostat, Placebo - Hypertension, Hypercortisolemia | Phase 4 | Not yet recruiting | RECORDATI GROUP | 63 | 2026-08-01 | 2025-12-10 |
| EndoSense: Continuous Real-Time Monitoring of Health Markers in Endocrine and Metabolic Disorders Sequential Dietary Sodium Modulation - Endocrine Disorders, Hypertension | Not applicable | Active not recruiting | Felix Beuschlein | 100 | 2026-07-03 | 2026-07-27 |
| IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion Intervention 1: Adrenalectomy, Intervention 2: Semaglutide - Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS) | Not applicable | Recruiting | University of Texas Southwestern Medical Center | 75 | 2026-03-05 | 2026-03-27 |
| Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS) Osilodrostat (Isturisa) - Mild Autonomous Cortisol Secretion (MACS) | Phase 4 | Recruiting | Johns Hopkins University | 10 | 2026-02-02 | 2026-03-05 |
| Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS) Osilodrostat 1 MG - Mild Autonomous Cortisol Secretion, Autonomous Cortisol Secretion (ACS) | Phase 2 | Recruiting | Mayo Clinic | 15 | 2026-01-14 | 2026-02-11 |
| Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) clofutriben, Placebo - Type 2 Diabetes, Cortisol Excess | Phase 2 | Recruiting | Sparrow Pharmaceuticals | 1500 | 2025-11-29 | 2026-10-06 |
| Metyrapone for Mild Autonomous Cortisol Secretion (MACS) Metyrapone - Autonomous Cortisol Secretion, Mild Autonomous Cortisol Secretion (MACS) | Phase 2 | Active not recruiting | Mayo Clinic | 30 | 2023-12-19 | 2026-09-25 |
| A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome atumelnant - Cushing Syndrome, Cushing Disease | Phase 1 / Phase 2 | Completed | Crinetics Pharmaceuticals Inc. | 19 | 2023-10-12 | 2026-10-14 |
| CXCR4 Targeted PET Imaging in APA Preoperative Localization Diagnosis CXCR4 - Aldosterone-Producing Adenoma | Not applicable | Unknown | Zhongnan Hospital | 50 | 2023-05-30 | 2023-07-17 |
| Cerebrovascular Disease: Quality of Life (CODE: QoL) questionnaire, hair samples, blood samples, clinical exam - Quality of Life, Stroke, Acute | Recruiting | University of Zurich | 680 | 2023-05-27 | 2024-06-05 | |
| PATHophysiology of OSteoporosis: Role of Hidden Cortisol Excess and Its Predictors in Bone Fragility Osteoporosis, Bone Fracture | Unknown | Istituto Auxologico Italiano | 1500 | 2023-04-24 | 2024-03-21 | |
| Effects of "Vitamin N" Nature Immersion Therapy on Stress Levels in Health Care Workers in the City of Bogotá Immersion therapy in nature - Vitamin N - Cortisol Excess, Stress, Psychological | Not applicable | Unknown | Jeadran N. Malagón-Rojas | 118 | 2022-10-15 | 2024-09-27 |
| SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome SPI-62, Placebo - Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion | Phase 2 | Completed | Sparrow Pharmaceuticals | 26 | 2022-09-01 | 2025-10-08 |
| An Exploratory Investigation of a Supplement to Promote Cognitive Health Benefits Heights Smart Supplement - Anxiety, Stress | Not applicable | Completed | Heights | 34 | 2022-06-15 | 2022-11-08 |
| Prevalence of Hidden Hypercortisolism in Osteoporosis Osteoporosis, Cortisol Excess | Unknown | Istituto Auxologico Italiano | 1000 | 2022-05-26 | 2023-03-09 | |
| Postmortem Evaluation of Adrenal and Other Endocrine Tumors in Patients With Sudden Death Adrenal aldosterone synthase (CYP11B2) staining, Adrenal cortisol synthase (CYP11B1) staining, Histopathological analysis - Primary Aldosteronism, Adrenal Cushing Syndrome | Active not recruiting | Helsinki University Central Hospital | 400 | 2022-02-03 | 2024-04-16 | |
| China Adrenal Disease Registry Cushing Syndrome, Aldosteronism | Unknown | Shanghai Jiao Tong University School of Medicine | 2000 | 2021-06-01 | 2022-02-14 | |
| Effect of Maternal Odor and Kangaroo Care on Serum Cortisol and Comfort Levels in Preterm Infants: a Randomised Trial Exposure to maternal odor - Preterm Birth Complication, Stress Related Disorder | Not applicable | Completed | Istanbul Nisantasi University | 92 | 2021-01-01 | 2022-11-07 |
| Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol) Relacorilant, Pembrolizumab - Adrenocortical Carcinoma | Phase 1 | Completed | Corcept Therapeutics | 15 | 2020-09-30 | 2024-02-23 |
Showing 20 of 43. Sign in to see all of them.
Cushing Syndrome (22) · Hypertension (11) · Pituitary ACTH Hypersecretion (10) · Adrenal Cortex Neoplasms (8) · Hyperaldosteronism (7) · Diabetes Mellitus, Type 2 (6) · Adrenal Hyperplasia, Congenital (5) · Adrenocortical Carcinoma (5) · Adrenal incidentaloma (4) · Pituitary Diseases (4) · Adrenal Gland Neoplasms (3) · Choristoma (3) · Hirsutism (3) · Pheochromocytoma (3)
Neoplasms (43) · Paraneoplastic Endocrine Syndromes (43) · Paraneoplastic Syndromes (43) · Adrenal Gland Diseases (31) · Endocrine System Diseases (31) · Adrenocortical Hyperfunction (26) · Nutritional and Metabolic Diseases (17) · Metabolic Diseases (16) · Neoplasms by Site (16) · Endocrine Gland Neoplasms (15) · Nervous System Diseases (13) · Brain Diseases (12) · Central Nervous System Diseases (12) · Vascular Diseases (12) · Adrenal Cortex Diseases (11)
relacorilant (5) · Mifepristone (4) · Osilodrostat (4) · Corlux (3) · Metyrapone (2) · pasireotide (2) · ASP3662 (1) · Blood Specimen Collection (1) · Forest Therapy (1) · Kangaroo-Mother Care Method (1) · Radiofrequency Ablation (1) · Staining and Labeling (1) · pembrolizumab (1)
Corcept Therapeutics (9) · Mayo Clinic (3) · Istituto Auxologico Italiano (2) · Novartis Pharmaceuticals (2) · Sparrow Pharmaceuticals (2) · Cedars-Sinai Medical Center (1) · Charles University, Czech Republic (1) · Crinetics Pharmaceuticals Inc. (1) · Felix Beuschlein (1) · Fondazione Poliambulanza Istituto Ospedaliero (1) · HRA Pharma (1) · Haukeland University Hospital (1) · Heights (1) · Helsinki University Central Hospital (1) · Istanbul Nisantasi University (1)
United States (22) · Italy (10) · Germany (5) · Netherlands (4) · Romania (4) · Spain (4) · Austria (3) · Bulgaria (3) · Canada (3) · France (3) · Israel (3) · Poland (3) · Turkey (Türkiye) (3) · China (2) · Sweden (2)
Andreas G Moraitis, MD (2) · Andreas Moraitis, MD (2) · Coleman Gross, MD (2) · Irina Bancos, MD (2) · Alev Sivasli (1) · Amir Hamrahian, MD (1) · Christopher Hill, PhD (1) · Coleman Gross (1) · Coleman Gross, M.D. (1) · Dilek Gogas Yavuz, M.D. (1) · Elisa Cairoli, MD (1) · Felix Beuschlein, Prof. Dr. med. (1) · Frank Czerwiec, MD (1)
PMID 25013998, PMID 26507877, PMID 35058882, PMID 10658825, PMID 15958281, PMID 16263996, PMID 18323730, PMID 19183121, PMID 19321267, PMID 1977988, PMID 21602959, PMID 22466348, PMID 23864443, PMID 23970725, PMID 25283590, PMID 26253288, PMID 26708842, PMID 26869575, PMID 27454103, PMID 28887710, PMID 29325527, PMID 29510982, PMID 29706798, PMID 30030986, PMID 30817193, PMID 31206616, PMID 31849839, PMID 32206838, PMID 33196558, PMID 34029490, PMID 34335465, PMID 35220871, PMID 3536461, PMID 35817047, PMID 35998969, PMID 36074157, PMID 36380152, PMID 36800277, PMID 36952249, PMID 37318239, PMID 37801655, PMID 38771379, PMID 39062179, PMID 39086899, PMID 39995489, PMID 41730814, PMID 6135282, PMID 7160336
2025 (2), 2008 (1), 2018 (1), 2023 (1), K23DK142038 (1)